Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Conditions
Brief summary
This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic cancer that has come back after a period of improvement (metastatic). Drugs used in chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether modified FOLFIRI and veliparib as second line therapy is more effective than FOLFIRI alone in treating metastatic pancreatic cancer.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the overall survival (OS) of metastatic pancreatic cancer patients treated with fluorouracil, irinotecan (irinotecan hydrochloride), leucovorin (leucovorin calcium), (modified FOLFIRI) and ABT-888 (veliparib) compared to a control arm of fluorouracil, irinotecan, and leucovorin (FOLFIRI). SECONDARY OBJECTIVES: I. To evaluate the frequency and severity of toxicity associated with each of the treatment arms in this patient population. II. To evaluate the progression-free survival (PFS) in each of the treatment arms in this patient population. III. To evaluate the overall response rate (confirmed and unconfirmed; complete response + partial response), disease control rate (confirmed and unconfirmed; complete response + partial response + stable disease), and duration of response in each of the treatment arms in this patient population. TERTIARY OBJECTIVES: I. To evaluate if breast cancer, early onset (BRCA)1 and BRCA2 mutations (somatic or germline) are associated with improved clinical outcomes (overall survival \[OS\], progression-free survival \[PFS\] and overall response rates \[ORR\]) in each treatment arm. II. To evaluate the impact of homologous recombination deficiency (HRD) score on clinical outcomes in each treatment arm. III. To evaluate the impact of genomic alterations identified by the BROCA-homologous recombinant (HR) assay, other than BRCA1/2, on clinical outcomes in each treatment arm. IV. To bank tissue for future translational medicine studies. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive veliparib orally (PO) twice daily (BID) every 12 hours on days 1-7, irinotecan hydrochloride intravenously (IV) over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5. ARM II: Patients receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 3 years.
Interventions
DRUGFluorouracil
Given IV
DRUGIrinotecan Hydrochloride
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGLeucovorin Calcium
Given IV
DRUGVeliparib
Given PO
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically documented pancreatic adenocarcinoma; patients with pancreatic neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible * Patients must have metastatic disease that is measurable; computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess measurable disease must have been completed within 28 days prior to registration; CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form * Patients must not have history of brain metastases * Patients must have had one and only one prior regimen of systemic therapy for metastatic disease unless the patient meets the criteria below * Prior systemic therapy and chemoradiotherapy for treatment of resectable, borderline resectable or locally advanced unresectable disease is allowed and does not count toward prior therapy for metastatic disease * Patients who received systemic therapy with gemcitabine/nab-paclitaxel for resectable or borderline/locally advanced unresectable disease and progressed with metastatic disease within 3 months of the past dose of systemic therapy are eligible * Patients must have completed systemic therapy at least 14 days prior to registration, any surgical procedure must have been performed at least 14 days prior to registration, and radiation therapy must be completed at least 7 days prior to registration; patients must have recovered from major side effects of prior therapies or procedures in the opinion of the local site investigator prior to registration * Patients must not have received prior irinotecan-based chemotherapy (e.g. irinotecan hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin \[FOLFIRINOX\] or FOLFIRI) * Patients must not have received prior PARP inhibitor therapy including, but not limited to ABT-888, olaparib, rucaparib, and talazoparib (BMN637) * Patients must have a Zubrod performance status of 0-1 * Within 14 days prior to registration: Absolute neutrophil count (ANC) \>= 1,500/mcL * Within 14 days prior to registration: Hemoglobin \>= 9 g/dL * Within 14 days prior to registration: Platelets \>= 100,000/mcL * Within 14 days prior to registration: Total bilirubin =\< 1.5 x institutional upper limit of normal (IULN) * Within 14 days prior to registration: Serum albumin \>= 3.0 g/dL * Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x IULN; patients with liver metastases may have AST and ALT of =\< 5.0 x IULN * Within 14 days prior to registration: Serum creatinine =\< 2.0 mg/dL * Patients must have CA19-9 obtained within 14 days prior to registration; if CA19-9 is normal a carcinoembryonic antigen (CEA) must be tested within 14 days prior to registration * Patients must have blood urea nitrogen (BUN), alkaline phosphatase, sodium, potassium, calcium, glucose, chloride, and bicarbonate levels obtained within 14 days prior to registration * Patients must not have any clinically significant and uncontrolled major medical condition(s) including, but not limited to uncontrolled nausea/vomiting/diarrhea; active uncontrolled infection; symptomatic congestive heart failure (New York Heart Association \[NYHA\] class \>= II); unstable angina pectoris or cardiac arrhythmia; psychiatric illness/social situation that would limit compliance with study requirements * Patients must not have active seizure or history of seizure * Patients must be able to swallow whole capsule * Patients must have a complete physical examination and medical history within 28 days prior to registration * Patients must not have known Gilbert's syndrome * Patients must not have known hypersensitivity to irinotecan, fluorouracil, or leucovorin * Patients of childbearing potential must have a negative pregnancy test within 28 days prior to registration and must not be nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method during the study and for 6 months following completion of treatment; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures * Patients must be willing and able to undergo a biopsy after signed consent and prior to registration; patients must have tumor tissue and blood samples available and be willing to submit tumor and blood samples; NOTE: core biopsy required; fine needle aspiration (FNA) is not an acceptable substitute for core biopsy * If archival tumor is available for submission, patients must be willing to submit tumor sample * Patients must be offered the opportunity to participate in specimen banking for future use * Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines * As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 3 years | OS: time to death by any cause from randomized treatment arm assignment. The log-rank test with stratification was used by prior systemic treatment for metastatic disease. Distributions of overall survival in arms 1 and 2 were estimated using the method of Kaplan-Meier. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Duration of treatment and follow up until death or 3 years post registration | Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. |
| Progression Free Survival (PFS) | From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years | From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of progression are censored at date of last contact. |
| Overall Response Rate, ORR | Up to 3 years post registration | Overall response rate (ORR) is defined as the proportion of participants who have a confirmed and unconfirmed, partial or complete response to therapy. |
| Disease Control Rate | Up to 3 years post registration | Disease control rate (DCR) is defined as the proportion of participants who have a confirmed and unconfirmed, partial, complete or stable response to therapy. |
| Duration of Response (DoR) | Up to 3 years post registration | DoR: time from date of first documentation of response (complete response, CR, or partial response, PR) to date of first documentation of progression or symptomatic deterioration, or death due to any cause among participants, who achieve a response (CR or PR). The distribution of DoR in each treatment arm will be estimated using the Kaplan-Meier method. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORElena G Chiorean
SWOG Cancer Research Network
Participant flow
Recruitment details
The trial was designed to enroll 143 patients, but was closed early based on the results of a planned interim futility analysis. Thus, only 123 patients were enrolled on the study.
Pre-assignment details
123 participants were enrolled, but 4 were ineligible and 2 refused assigned FOLFIRI treatment. Thus, 117 were eligible for analyses.
Participants by arm
| Arm | Count |
|---|---|
| Arm I (Veliparib and mFOLFIRI) Participants receive veliparib PO BID every 12 hours on days 1-7, irinotecan hydrochloride IV over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5.
Fluorouracil: Given IV
Irinotecan Hydrochloride: Given IV
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Veliparib: Given PO | 59 |
| Arm II (FOLFIRI) Participants receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3.
Fluorouracil: Given IV
Fluorouracil: Given IV bolus
Irinotecan Hydrochloride: Given IV
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV | 58 |
| Total | 117 |
Baseline characteristics
| Characteristic | Arm II (FOLFIRI) | Total | Arm I (Veliparib and mFOLFIRI) |
|---|---|---|---|
| Age, Continuous | 67 years | 67 years | 67 years |
| Prior treatment for metastic pancreatic adenocarcinoma No | 6 Participants | 12 Participants | 6 Participants |
| Prior treatment for metastic pancreatic adenocarcinoma Yes | 52 Participants | 105 Participants | 53 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 9 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 6 Participants | 1 Participants |
| Race (NIH/OMB) White | 47 Participants | 99 Participants | 52 Participants |
| Sex: Female, Male Female | 25 Participants | 53 Participants | 28 Participants |
| Sex: Female, Male Male | 33 Participants | 64 Participants | 31 Participants |
| Zubrod (ECOG) Performance Status 0 | 23 Participants | 37 Participants | 14 Participants |
| Zubrod (ECOG) Performance Status 1 | 35 Participants | 80 Participants | 45 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 56 / 59 | 56 / 58 |
| other Total, other adverse events | 55 / 56 | 49 / 50 |
| serious Total, serious adverse events | 23 / 56 | 6 / 50 |
Outcome results
Primary
Overall Survival (OS)
OS: time to death by any cause from randomized treatment arm assignment. The log-rank test with stratification was used by prior systemic treatment for metastatic disease. Distributions of overall survival in arms 1 and 2 were estimated using the method of Kaplan-Meier.
Time frame: Up to 3 years
Population: All eligible participants according to the intent-to-treat principle.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I (Veliparib and mFOLFIRI) | Overall Survival (OS) | 5.4 months |
| Arm II (FOLFIRI) | Overall Survival (OS) | 6.5 months |
p-value: 0.2895% CI: [0.85, 1.78]Log Rank
Secondary
Disease Control Rate
Disease control rate (DCR) is defined as the proportion of participants who have a confirmed and unconfirmed, partial, complete or stable response to therapy.
Time frame: Up to 3 years post registration
Population: Eligible participants with measurable disease.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Veliparib and mFOLFIRI) | Disease Control Rate | 0.32 proportion of participants |
| Arm II (FOLFIRI) | Disease Control Rate | 0.47 proportion of participants |
Secondary
Duration of Response (DoR)
DoR: time from date of first documentation of response (complete response, CR, or partial response, PR) to date of first documentation of progression or symptomatic deterioration, or death due to any cause among participants, who achieve a response (CR or PR). The distribution of DoR in each treatment arm will be estimated using the Kaplan-Meier method.
Time frame: Up to 3 years post registration
Population: Eligible participants with measurable disease, and who had confirmed partial response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I (Veliparib and mFOLFIRI) | Duration of Response (DoR) | 3.4 months |
| Arm II (FOLFIRI) | Duration of Response (DoR) | 5.1 months |
Secondary
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.
Time frame: Duration of treatment and follow up until death or 3 years post registration
Population: Patients who received at least one dose of protocol treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Alanine aminotransferase increased | 2 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fatigue | 10 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cardiac disorders - Other, specify | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Febrile neutropenia | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anorexia | 3 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fever | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Catheter related infection | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Generalized muscle weakness | 2 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Acute coronary syndrome | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyperglycemia | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Confusion | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypertension | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Aspartate aminotransferase increased | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypokalemia | 2 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cough | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyponatremia | 2 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Alkaline phosphatase increased | 2 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypotension | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dehydration | 6 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Infections and infestations - Other, specify | 2 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Atrial fibrillation | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Lymphocyte count decreased | 3 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Device related infection | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Mucositis oral | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Abdominal pain | 2 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Nausea | 7 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Diarrhea | 6 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Neutrophil count decreased | 20 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Atrial flutter | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Platelet count decreased | 4 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dyspnea | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sepsis | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anemia | 4 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Thromboembolic event | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Enterocolitis infectious | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vascular disorders - Other, specify | 1 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Blood bilirubin increased | 4 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vomiting | 5 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fall | 0 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | White blood cell decreased | 7 Participants |
| Arm I (Veliparib and mFOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Abdominal infection | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | White blood cell decreased | 3 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Abdominal infection | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Abdominal pain | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Acute coronary syndrome | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Alanine aminotransferase increased | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Alkaline phosphatase increased | 3 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anemia | 5 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anorexia | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Aspartate aminotransferase increased | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Atrial fibrillation | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Atrial flutter | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Blood bilirubin increased | 5 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cardiac disorders - Other, specify | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Catheter related infection | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Confusion | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cough | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dehydration | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Device related infection | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Diarrhea | 3 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dyspnea | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Enterocolitis infectious | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fall | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fatigue | 3 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Febrile neutropenia | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fever | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Generalized muscle weakness | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyperglycemia | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypertension | 2 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypokalemia | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyponatremia | 3 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypotension | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Infections and infestations - Other, specify | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Lymphocyte count decreased | 6 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Mucositis oral | 1 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Nausea | 2 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Neutrophil count decreased | 11 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Platelet count decreased | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sepsis | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Thromboembolic event | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vascular disorders - Other, specify | 0 Participants |
| Arm II (FOLFIRI) | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vomiting | 2 Participants |
Secondary
Overall Response Rate, ORR
Overall response rate (ORR) is defined as the proportion of participants who have a confirmed and unconfirmed, partial or complete response to therapy.
Time frame: Up to 3 years post registration
Population: Eligible participants with measurable disease.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Veliparib and mFOLFIRI) | Overall Response Rate, ORR | 0.09 proportion of participants |
| Arm II (FOLFIRI) | Overall Response Rate, ORR | 0.10 proportion of participants |
Secondary
Progression Free Survival (PFS)
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of progression are censored at date of last contact.
Time frame: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
Population: All eligible participants according to the intent-to-treat principle.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I (Veliparib and mFOLFIRI) | Progression Free Survival (PFS) | 2.1 months |
| Arm II (FOLFIRI) | Progression Free Survival (PFS) | 2.9 months |
p-value: 0.0995% CI: [0.96, 2.02]Log Rank
Other Pre-specified
Genomic Alterations Identified by the BROCA-homologous Recombinant (HR) Assay
Time frame: Baseline
Other Pre-specified
Homologous Recombination Deficiency (HRD) Score
The impact of HRD positivity will be evaluated on clinical outcomes in each treatment arm. The HRD score is the unweighted sum of loss of heterozygosity footprint, telomeric allelic imbalance, and large-scale state transitions measurements on a scale from 0-100. The HRD score threshold for positivity in this population will be estimated by applying receiver operating characteristic curves, classifying patients by overall disease response.
Time frame: Baseline
Other Pre-specified
Prevalence of BRCA1 and BRCA2 Mutations (Somatic or Germline)
BRCA1/2 mutations will be associated with clinical outcomes (OS, PFS, and overall response rate \[ORR\]).
Time frame: Baseline